Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 10, 2026

Axalta targets $1.14B–$1.17B adjusted EBITDA in 2026 as merger with AkzoNobel advances

View original at seekingalpha.com
Axalta targets $1.14B–$1.17B adjusted EBITDA in 2026 as merger with AkzoNobel advances Earnings Call Insights: Axalta Coating Systems Ltd…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Axalta achieved 2% pricing in Refinish in 2025 and targets to stay consistent at 2% net for 2026

    80% confidence
  • Asia Pacific showed strength with 5% net sales growth in Industrial segment while North America and Europe remain sluggish

    80% confidence
  • Free cash flow came in at $466 million in 2025, an increase of over $300 million compared to 2022

    80% confidence
  • Refinish volumes are expected to be flat to slightly up for 2026

    80% confidence
  • Interest expense declined 11%, SG&A expenses were down 8%, and other fixed operating costs were down 4% compared to Q4 2024

    80% confidence
  • Axalta achieved record annual financial performance with adjusted EBITDA margins expanding over 500 basis points to 22% and adjusted diluted EPS up about 55% since 2022

    80% confidence
  • 2026 price-mix is expected to be up low single digits with flattish volumes

    80% confidence
  • The combined Axalta-AkzoNobel entity will be the largest global performance coatings company and second largest paints and coatings company

    80% confidence
  • Axalta grew 400 body shops in North America in 2025 despite market challenges

    80% confidence
  • Destocking was worse than expected but is expected to abate in Q2 2026

    80% confidence
  • Q4 2025 marks the seventh consecutive quarter at or above the A Plan margin target of 21%

    80% confidence
  • Q4 net sales declined 4% year-over-year due to lower volumes in North America across all businesses

    80% confidence
  • In Refinish, Axalta is stronger in premium while AkzoNobel is stronger in economy, creating complementary capabilities

    80% confidence
  • The merger with AkzoNobel is an extraordinary value creation opportunity that will create a global leader with phenomenal scale, significant free cash flow, EBITDA margins approaching 20%, investment-grade rating, and $600 million in synergies

    80% confidence
  • Axalta delivered another period of strong operational execution, solid margin performance and record cash generation in Q4 2025

    80% confidence
  • 2026 will start off slower in Q1 with recovery beginning in Q2 and building momentum into the second half

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com